The U.S. Food and Drug Administration (FDA) said in a safety alert that some widely used treatments for Type 2 diabetes can cause severe and disabling joint pain, raising concerns for a big-selling class of drugs. The FDA alert applies to a category of pills known as DPP-IV inhibitors, which include AstraZeneca PLC’s diabetes drug Onglyza, and Tradjenta. Via The Wall Street Journal. Posted August 28, 2015.
Alanna McCatty is a recent graduate of Pace University with a degree in communications. At MedShadow, she reports on new findings and research on the side effects of prescription drugs.